NYSEAMERICAN:MTNB Matinas BioPharma (MTNB) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free MTNB Stock Alerts $0.27 -0.03 (-9.17%) (As of 08:58 AM ET) Add Compare Share Share Today's Range$0.27▼$0.2750-Day Range N/A52-Week Range$0.11▼$0.89Volume26,565 shsAverage Volume848,635 shsMarket Capitalization$59.20 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Matinas BioPharma alerts: Email Address Matinas BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,000.9% Upside$3.00 Price TargetShort InterestHealthy0.68% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 1,000.9% from its current price of $0.27.Amount of Analyst CoverageMatinas BioPharma has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.68% of the outstanding shares of Matinas BioPharma have been sold short.Short Interest Ratio / Days to CoverMatinas BioPharma has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Matinas BioPharma has recently increased by 22.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MTNB. Previous Next 2.3 News and Social Media Coverage News SentimentMatinas BioPharma has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 1 article on an average week.Search Interest6 people have searched for MTNB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Matinas BioPharma is held by insiders.Percentage Held by InstitutionsOnly 11.90% of the stock of Matinas BioPharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Matinas BioPharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Matinas BioPharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMatinas BioPharma has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Matinas BioPharma Stock (NYSEAMERICAN:MTNB)Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.Read More MTNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MTNB Stock News HeadlinesMarch 3, 2024 | uk.finance.yahoo.comMatinas BioPharma Holdings, Inc. (MTNB)February 28, 2024 | wsj.comMatinas BioPharma Holdings Inc.March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 26, 2024 | finance.yahoo.comMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionFebruary 23, 2024 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 20, 2024 | globenewswire.comMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisFebruary 4, 2024 | seekingalpha.comAVBP ArriVent BioPharma, Inc.March 19, 2024 | Paradigm Press (Ad)Biden out June 13?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.January 21, 2024 | morningstar.comMatinas BioPharma Holdings Inc MTNBJanuary 3, 2024 | finance.yahoo.comMatinas BioPharma to Present at Biotech Showcase 2024December 27, 2023 | finance.yahoo.comMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesDecember 21, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 21, 2023 | markets.businessinsider.comMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203December 21, 2023 | finance.yahoo.comMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDADecember 20, 2023 | benzinga.comMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and ForecastNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)November 10, 2023 | finance.yahoo.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Matinas BioPharma Holdings Inc Earnings CallNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business ProgressNovember 8, 2023 | finance.yahoo.comMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 7, 2023 | finanznachrichten.deMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelNovember 7, 2023 | finance.yahoo.comMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelNovember 1, 2023 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023October 13, 2023 | msn.comBTIG Reiterates Matinas Biopharma Holdings (MTNB) Buy RecommendationOctober 11, 2023 | marketwatch.comMatinas BioPharma Shares Double After Patient Achieves Clinical ResolutionSee More Headlines Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2023Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:MTNB CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees34Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,000.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,000,000.00 Net MarginsN/A Pretax Margin-984.81% Return on Equity-70.72% Return on Assets-57.90% Debt Debt-to-Equity RatioN/A Current Ratio6.19 Quick Ratio6.19 Sales & Book Value Annual Sales$3.19 million Price / Sales18.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book1.60Miscellaneous Outstanding Shares217,260,000Free Float196,408,000Market Cap$59.20 million OptionableNot Optionable Beta1.52 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jerome D. Jabbour J.D. (Age 50)Co-Founder, CEO, President & Director Comp: $881.5kDr. Theresa Matkovits Ph.D. (Age 57)Chief Development Officer Comp: $601kDr. James J. Ferguson FACC (Age 70)M.D., Chief Medical Officer Comp: $619.92kMr. Keith A. Kucinski CPA (Age 54)M.B.A., Chief Financial Officer Comp: $249.05kDr. Hui Liu M.B.A. (Age 56)Ph.D., Chief Technology Officer Mr. Frank CalamusaExecutive Director and Head of Manufacturing & Supply ChainMr. Thomas J. Hoover M.B.A. (Age 54)Chief Business Officer More ExecutivesKey CompetitorsAcerus PharmaceuticalsOTCMKTS:TRLPFCleneNASDAQ:CLNNHCW BiologicsNASDAQ:HCWBGain TherapeuticsNASDAQ:GANXSCYNEXISNASDAQ:SCYXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 564,020 shares on 3/11/2024Ownership: 4.289%Virtu Financial LLCBought 162,885 shares on 2/26/2024Ownership: 0.075%Vanguard Group Inc.Bought 564,020 shares on 2/15/2024Ownership: 4.289%Private Advisor Group LLCBought 80,000 shares on 2/6/2024Ownership: 0.155%Sargent Investment Group LLCSold 105,000 shares on 2/5/2024Ownership: 1.757%View All Institutional Transactions MTNB Stock Analysis - Frequently Asked Questions Should I buy or sell Matinas BioPharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MTNB shares. View MTNB analyst ratings or view top-rated stocks. What is Matinas BioPharma's stock price target for 2024? 1 analysts have issued 1 year target prices for Matinas BioPharma's shares. Their MTNB share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,000.9% from the stock's current price. View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 1,470,000 shares, an increase of 22.5% from the February 14th total of 1,200,000 shares. Based on an average trading volume of 959,200 shares, the days-to-cover ratio is presently 1.5 days. View Matinas BioPharma's Short Interest. When is Matinas BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MTNB earnings forecast. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) posted its earnings results on Wednesday, August, 9th. The company reported ($0.03) EPS for the quarter. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS). Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.29%), Vanguard Group Inc. (4.29%), Sargent Investment Group LLC (1.76%), Arkadios Wealth Advisors (0.75%), Private Advisor Group LLC (0.16%) and Virtu Financial LLC (0.07%). View institutional ownership trends. How do I buy shares of Matinas BioPharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MTNB) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.